Updated TACTI-mel Data Presented at the Cambridge Healthtech Institute’s Immuno-Oncology Summit
SYDNEY, Australia, March 22, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) (“Immutep” or the “Company”) is pleased to announce the presentation of updated data from its TACTI-mel Phase I clinical trial in Australia investigating the use …